T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, ) In all T1...

26
indication T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, ) In all T1 patients failing intravesical therapy muscle-invasive bladder cancer T2-T4a, N0-Nx, M0 BCG-resistant Tis extensive papillary disease

Transcript of T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, ) In all T1...

Page 1: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

indication

T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )

In all T1 patients failing intravesical therapy

muscle-invasive bladder cancer T2-T4a, N0-Nx, M0

BCG-resistant Tis extensive papillary disease

Page 2: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

performance status and age influence the choice of primary therapy, as well as type of urinary diversion with cystectomy being reserved for younger patients without concomitant disease and better performance status

Page 3: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Timing and delay of cystectomy

delay of treatment beyond 90 days of primary diagnosis caused a significant increase in extravesical disease (81 vs 52%)

Page 4: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Before cystectomy, the patient should be counselled adequately

regarding all possible alternatives, and the final decision should be based on a consensus between

patient and surgeon.

Page 5: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Technique and extent

prostate and seminal urothelial cancer in the prostate was detected in 33% in23-54% of patients a prostate cancer is found

uterus and adnexa in women spare seminal vesicles and the

prostatic capsule

Page 6: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Role of Lymphadenectomy provides insight into the local extent In limited nodal burden increase

survival

Page 7: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

dissection of regional lymph nodes.

There is a substantial amount of literature about the extent of lymphadenectomy.

Yet, data regarding its clinical significance are controversial

In retrospective studies extended lymphadenectomy (removal of the

obturator, internal, external, common iliac and presacral nodes as well as

nodes at the aortic bifurcation) has been reported to improve survival

Page 8: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

standard lymph node dissection

genitofemoral nerve laterally internal iliac artery medially Cooper ligament caudally, and the crossing of the ureter at

the common iliac artery cranially

Page 9: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 10: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 11: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 12: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 13: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 14: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 15: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 16: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 17: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 18: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 19: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 20: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 21: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Ileal Conduit

It is simplest type of conduit diversion to perform and isassociated with the fewest intraoperative and immediatepostoperative complications

Page 22: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Colon Conduit

transverse colon is used when one wants to be surethat the segment of conduit employed has not been irradiated

sigmoid conduit is a good choice in patients undergoing a pelvic exenteration who will have a colostomy

Page 23: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 24: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.

Contra-indications continent urinary diversion

• Debilitating neurological and psychiatric illnesses.

• Limited life expectancy.• Impaired liver or renal function.• Transitional cell carcinoma of the

urethral margin or other surgical margins

Page 25: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.
Page 26: T1 tumors at high risk of progression (high grade, multifocality, CIS, and tumor size, )  In all T1 patients failing intravesical therapy  muscle-invasive.